IceCure Reports 5-Year Top-Line Results From ICESECRET Kidney Cancer Cryoablation Study 

March 25, 2026—IceCure Medical Ltd. announced positive top-line results from its ICESECRET clinical trial of its ProSense cryoablation system for the treatment of small renal masses (SRMs) in kidney cancer patients.

The prospective, multicenter, single-arm clinical trial is being conducted at Bnai Zion Medical Center in Haifa, Israel, and at Shamir Medical Center in Be’er Ya’akov, Israel. Professor Halahmi Sarel, MD, is Principal Investigator of the ICESECRET trial.

According to the company, the trial included 114 patients (138 lesions) with localized SRMs of ≤ 5 cm ablated with ProSense cryoablation under CT guidance. Follow-up visits were performed at 6 weeks, 6 months, 1 year, and then annually up to 5 years after the procedure using ProSense.

At follow up visits, investigators collected data related to local recurrence based on CT imaging. Safety was determined by monitoring procedure-related adverse events throughout the study.

The press release noted that investigators evaluated 112 of the 114 enrolled patients at a median follow-up of 4 years (interquartile range, 1.4–5.3). The findings demonstrated that 83.9% of patients were recurrence-free at the median follow-up period. Among these patients, 12 underwent a second cryoablation procedure at a mean of 1.73 ± 1.2 years. In a subgroup of patients with tumors ≤ 3 cm, no previous kidney cancer, and successful initial procedures, the recurrence-free rate reached 89.4%.

The company advised that more detailed data from the study will be presented by Prof. Sarel at ECIO 2026, the European Conference on Interventional Oncology being held April 26-30 in Basel, Switzerland.

ProSense is currently approved in the United States, Europe, and other key markets for the treatment of malignant and benign kidney tumors, noted IceCure Medical.